LGVN Stock Price, Longeveron Inc. Quote, Chart

Market Summary

USD1.76-0.05

Market Closed

-2.76%

LGVN Alerts

3 major insider buys recently.

LGVN Stock Price

View Fullscreen

LGVN RSI Chart

LGVN Valuation

Market Cap

3.8M

Price/Earnings (Trailing)

-0.18

Price/Sales (Trailing)

5.4

Price/Free Cashflow

-0.2

LGVN Price/Sales (Trailing)

LGVN Profitability

Operating Margin

31.17%

Return on Equity

-317.65%

Return on Assets

-177.29%

Free Cashflow Yield

-504.61%

LGVN Fundamentals

LGVN Revenue

Revenue (TTM)

709.0K

Rev. Growth (Yr)

-78.35%

Rev. Growth (Qtr)

-58%

LGVN Earnings

Earnings (TTM)

-21.4M

Earnings Growth (Yr)

-35.25%

Earnings Growth (Qtr)

-18.06%

Breaking Down LGVN Revenue

Last 7 days

0.6%

Last 30 days

-29.6%

Last 90 days

-68.5%

Trailing 12 Months

-94.1%

How does LGVN drawdown profile look like?

LGVN Financial Health

Current Ratio

1.5

Debt/Equity

0.28

Debt/Cashflow

-10.03

LGVN Investor Care

Shares Dilution (1Y)

3.65%

Diluted EPS (TTM)

-10.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	961.0K	877.0K	793.0K	709.0K
2022	1.3M	937.0K	970.0K	1.1M
2021	0	0	0	1.3M
2020	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Longeveron Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	soffer rock	bought	75,000	2.35	31,915	-
Apr 11, 2024	hashad mohamed wa'el ahmed	bought	24,999	2.35	10,638	chief executive officer
Apr 11, 2024	hare joshua	bought	99,999	2.35	42,553	chief scientific officer
Apr 10, 2024	hare joshua	bought	250,000	2.35	106,383	chief scientific officer
Apr 10, 2024	soffer rock	bought	250,000	2.35	106,383	-
Mar 12, 2024	hashad mohamed wa'el ahmed	sold (taxes)	-17,747	0.54	-32,866	chief executive officer
Mar 12, 2024	hashad mohamed wa'el ahmed	acquired	-	-	80,200	chief executive officer
Jan 10, 2024	ross cathy	bought	6,544	1.3089	5,000	-
Jan 02, 2024	hashad mohamed wa'el ahmed	sold (taxes)	-6,762	1.32	-5,123	chief executive officer
Jan 02, 2024	agafonova nataliya	sold (taxes)	-4,057	1.32	-3,074	chief medical officer

Which funds bought or sold LGVN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	LGT Financial Advisors LLC	sold off	-100	-486	-	-%
May 02, 2024	LGT Financial Advisors LLC	new	-	114	114	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	NORDEN GROUP LLC	sold off	-100	-19,652	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	1,647	3,641	4,039	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.24	-168,974	259,726	-%
Feb 15, 2024	TOWNSQUARE CAPITAL LLC	unchanged	-	-14,161	19,652	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-47,377	-	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-14,208	20,128	-%

Are Funds Buying or Selling LGVN?

Are funds buying LGVN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LGVN

No. of Funds

LGVN Alerts

3 major insider buys recently.

Unveiling Longeveron Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	intracoastal capital, llc	4.99%	174,054	SC 13G
Apr 15, 2024	hare joshua	25.7%	1,084,888	SC 13D/A
Feb 14, 2024	armistice capital, llc	7.31%	1,836,000	SC 13G
Dec 18, 2023	hare joshua	48.3%	7,988,167	SC 13D/A
May 25, 2022	soffer donald m	0%	0	SC 13D/A

Recent SEC filings of Longeveron Inc.

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	S-1	Initial Public Offering
Apr 25, 2024	D	D
Apr 18, 2024	8-K	Current Report
Apr 17, 2024	EFFECT	EFFECT
Apr 17, 2024	424B4	Prospectus Filed
Apr 17, 2024	SC 13G	Major Ownership Report
Apr 16, 2024	S-1/A	Initial Public Offering
Apr 15, 2024	SC 13D/A	13D - Major Acquisition
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Longeveron Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Longeveron Inc. News

Latest updates

Longeveron Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-58.0%	63.00	150	215	279	291	265	126	370	209	232	489	376	1,121	1,865	876	1,708
Cost Of Revenue	-32.3%	65.00	96.00	124	203	109	173	306	205	140	68.00	281	227	651	1,492	764	896
Gross Profit	-103.7%	-2.00	54.00	93.00	76.00	13.00	92.00	160	165	69.00	164	208	149	529	373	112	812
Operating Expenses	4.3%	5,438	5,215	5,805	4,792	5,254	5,279	4,381	3,559	4,101	5,069	5,270	3,607	1,911	1,331	1,338	1,025
S&GA Expenses	-27.5%	203	280	143	157	285	245	234	287	834	25.00	53.00	550	59.00	44.00	47.00	50.00
R&D Expenses	17.0%	2,156	1,843	2,287	2,780	3,331	2,960	1,720	1,292	1,734	2,048	1,960	1,350	1,155	585	642	289
Interest Expenses	-	-	-	-	-	1,397	-	-	-	1.00	1.00	2.00	-	-	4.00	-	-
Net Income	-18.1%	-6,028	-5,106	-5,632	-4,647	-4,457	-5,244	-5,624	-3,510	-4,069	-4,855	-5,010	-3,111	-1,355	-938	-1,216	-213
Net Income Margin	-20.7%	-30.20*	-25.02*	-22.78*	-20.78*	-17.90*	-19.02*	-19.27*	-13.42*	-13.05*	-	-	-	-	-	-	-
Free Cashflow	8.7%	-4,161	-4,559	-4,693	-5,890	-2,374	-4,612	-3,353	-4,199	-1,593	-2,358	-2,939	-3,019	-492	-246	-1,229	-528

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	3.9%	12,078	11,625	17,093	21,808	27,413	30,515	35,325	39,173	42,766	27,150	29,857	32,432	9,240
Current Assets	15.9%	5,848	5,044	10,292	14,870	20,280	23,237	28,238	31,867	35,380	19,665	22,111	25,297	1,849
Cash Equivalents	151.6%	4,949	1,967	2,747	4,984	10,503	13,574	20,224	22,132	25,658	9,738	16,833	24,461	816
Net PPE	-0.6%	2,529	2,544	2,717	2,810	2,949	3,064	2,835	2,966	3,062	3,070	3,234	3,417	3,597
Liabilities	6.9%	5,337	4,993	5,830	5,490	6,910	5,900	5,944	4,867	5,313	4,817	5,207	5,937	7,283
Current Liabilities	14.6%	3,889	3,394	4,082	3,595	4,869	3,715	3,618	2,400	2,708	1,932	2,185	2,781	3,830
Long Term Debt	-	-	-	-	1,895	2,041	2,185	2,326	-	2,605	143	145	146	311
Shareholder's Equity	1.6%	6,741	6,632	11,263	16,318	20,503	24,615	29,381	34,306	37,453	22,333	24,650	26,495	1,957
Retained Earnings	-7.6%	-84,984	-78,956	-73,052	-67,420	-62,773	-58,316	-53,072	-47,448	-43,938	-39,869	-35,014	-30,004	-
Additional Paid-In Capital	6.8%	91,800	85,976	84,729	84,116	83,712	83,010	82,532	81,833	81,470	62,283	59,745	56,580	-
Shares Outstanding	2.6%	2,173	2,118	2,107	2,103	2,097	2,095	2,093	2,091	1,892	1,854	1,825	-	1,602
Float	-	-	-	19,016	-	-	-	18,000	-	-	-	26,000	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	12.3%	-3,997	-4,556	-4,601	-5,848	-2,308	-4,234	-3,275	-4,152	-1,281	-2,371	-2,952	-3,032	-505	-233	-1,228	-398
Share Based Compensation	-	-	-	-	-	476	293	-	-	-4,681	5,714	-1,001	1,265	-	-	31.00	13.00
Cashflow From Investing	-59.1%	1,564	3,826	2,450	346	-570	-2,389	1,515	767	-1,315	-4,724	-	-	-40.00	-40.00	-41.00	-140
Cashflow From Financing	10930.0%	5,415	-50.00	-86.00	-17.00	-193	-27.00	-148	-141	18,516	-	-19.00	26,677	-33.00	8.00	450	1,150

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LGVN Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 709	$ 1,222
Cost of revenues	488	725
Gross profit	221	497
Operating expenses
General and administrative	11,401	8,119
Research and development	9,066	9,370
Sales and marketing	783	1,051
Total operating expenses	21,250	18,540
Loss from operations	(21,029)	(18,043)
Other (expense) and income
Lawsuit expense	(30)	(1,398)
Other refundable tax credits	23	306
Other (expense) income, net	(377)	300
Total other expenses, net	(384)	(792)
Net loss	(21,413)	(18,835)
Dividend attributable to warrant down round feature	(798)
Net loss attributable to common stockholders	$ (22,211)	$ (18,835)
Basic net loss per share (in Dollars per share)	$ (1.02)	$ (0.9)
Basic weighted average common shares outstanding (in Shares)	21,734,901	20,969,032
Grant revenue
Revenues
Total revenues	$ 41	$ 282
Clinical trial revenue
Revenues
Total revenues	$ 668	$ 940

LGVN Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,949	$ 10,503
Marketable equity securities	412	9,155
Prepaid expenses and other current assets	376	404
Accounts and grants receivable	111	218
Total current assets	5,848	20,280
Property and equipment, net	2,529	2,949
Intangible assets, net	2,287	2,409
Operating lease asset	1,221	1,531
Other assets	193	244
Total assets	12,078	27,413
Current liabilities:
Accounts payable	638	1,751
Accrued expenses	2,152	650
Current portion of operating lease liability	593	564
Estimated lawsuit liability		1,398
Deferred revenue	506	506
Total current liabilities	3,889	4,869
Long-term liabilities:
Long-term portion of operating lease liability	1,448	2,041
Total long-term liabilities	1,448	2,041
Total liabilities	5,337	6,910
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2023 and December 31, 2022
Additional paid-in capital	91,800	83,712
Stock subscription receivable	(100)	(100)
Accumulated deficit	(84,984)	(62,773)
Accumulated other comprehensive loss		(357)
Total stockholders’ equity	6,741	20,503
Total liabilities and stockholders’ equity	12,078	27,413
Class A Common Stock
Stockholders’ Equity:
Common stock value	10	6
Class B Common Stock
Stockholders’ Equity:
Common stock value	$ 15	$ 15

About Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

CEO	Mr. Mohamed Wa'el Ahmed Hashad
WEBSITE	https://longeveron.com
INDUSTRY	Biotechnology
EMPLOYEES	19

Longeveron Inc. Frequently Asked Questions

What is the ticker symbol for Longeveron Inc.? What does LGVN stand for in stocks?

LGVN is the stock ticker symbol of Longeveron Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Longeveron Inc. (LGVN)?

As of Fri May 03 2024, market cap of Longeveron Inc. is 3.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LGVN stock?

You can check LGVN's fair value in chart for subscribers.

What is the fair value of LGVN stock?

You can check LGVN's fair value in chart for subscribers. The fair value of Longeveron Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Longeveron Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LGVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Longeveron Inc. a good stock to buy?

The fair value guage provides a quick view whether LGVN is over valued or under valued. Whether Longeveron Inc. is cheap or expensive depends on the assumptions which impact Longeveron Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGVN.

What is Longeveron Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, LGVN's PE ratio (Price to Earnings) is -0.18 and Price to Sales (PS) ratio is 5.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGVN PE ratio will change depending on the future growth rate expectations of investors.